AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Diacylglycerol lipase-beta

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NCG7

UPID:

DGLB_HUMAN

Alternative names:

KCCR13L; PUFA-specific triacylglycerol lipase; Sn1-specific diacylglycerol lipase beta

Alternative UPACC:

Q8NCG7; A4D2P3; B3KV90; B4DQU0; Q6PIX3; Q8N2N2; Q8N9S1; Q8TED3; Q8WXE6

Background:

Diacylglycerol lipase-beta (DAGL-beta), known by alternative names such as KCCR13L and PUFA-specific triacylglycerol lipase, is a pivotal enzyme in lipid metabolism. It catalyzes the hydrolysis of arachidonic acid-esterified diacylglycerols to produce 2-arachidonoylglycerol (2-AG), a principal endocannabinoid. This enzyme preferentially targets DAGs at the sn-1 position in a calcium-dependent manner, playing a crucial role in regulating 2-AG and arachidonic acid pools for eicosanoid production via cyclooxygenase pathways.

Therapeutic significance:

Understanding the role of Diacylglycerol lipase-beta could open doors to potential therapeutic strategies, particularly in modulating inflammatory responses and lipid mediator production.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.